[go: up one dir, main page]

WO2003087124A3 - Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales - Google Patents

Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales Download PDF

Info

Publication number
WO2003087124A3
WO2003087124A3 PCT/US2003/010240 US0310240W WO03087124A3 WO 2003087124 A3 WO2003087124 A3 WO 2003087124A3 US 0310240 W US0310240 W US 0310240W WO 03087124 A3 WO03087124 A3 WO 03087124A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood vessels
tumor
tumor cells
melecules
hmgn2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/010240
Other languages
English (en)
Other versions
WO2003087124A2 (fr
Inventor
Erkki Ruoslahti
Kimmo Porkka
Sven Christian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/400,083 external-priority patent/US7544767B2/en
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Priority to AU2003228431A priority Critical patent/AU2003228431A1/en
Publication of WO2003087124A2 publication Critical patent/WO2003087124A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003087124A3 publication Critical patent/WO2003087124A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait à un conjugué comprenant une groupe fonctionnel thérapeutique lié à un molécule à écotaxie se dirigeant de manière sélective vers des vaisseaux sanguins tumoraux et des cellules tumorales et se liant de manière spécifique au récepteur lié par le peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). L'invention a trait également à des procédés d'orientation d'un conjugué de l'invention vers des vaisseaux sanguins tumoraux et des cellules tumorales et d'utilisation d'un conjugué pour le traitement du cancer.
PCT/US2003/010240 2002-04-05 2003-04-02 Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales Ceased WO2003087124A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003228431A AU2003228431A1 (en) 2002-04-05 2003-04-02 Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11686602A 2002-04-05 2002-04-05
US10/116,866 2002-04-05
US10/400,083 2003-03-20
US10/400,083 US7544767B2 (en) 2002-04-05 2003-03-20 HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells

Publications (2)

Publication Number Publication Date
WO2003087124A2 WO2003087124A2 (fr) 2003-10-23
WO2003087124A3 true WO2003087124A3 (fr) 2006-08-17

Family

ID=29253938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010240 Ceased WO2003087124A2 (fr) 2002-04-05 2003-04-02 Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales

Country Status (2)

Country Link
AU (1) AU2003228431A1 (fr)
WO (1) WO2003087124A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CN102539734B (zh) * 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
CN108707584A (zh) 2009-11-17 2018-10-26 Musc研究发展基金会 针对人核仁素的人单克隆抗体
WO2011119058A2 (fr) 2010-03-22 2011-09-29 Universidade De Coimbra Nanoparticules lipidiques vectorisées par le peptide f3, utiles pour le traitement de maladies liées à une angiogenèse
CA2795289A1 (fr) * 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methodes et compositions pour une administration amelioree de composes
PL3446714T3 (pl) 2011-06-02 2021-11-22 University Of Louisville Research Foundation, Inc. Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
WO2016172515A1 (fr) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Système d'administration ciblée et procédés d'utilisation correspondants
EP3291839A1 (fr) 2015-05-05 2018-03-14 The University of Louisville Research Foundation, Inc. Nanoparticules conjuguées à un agent antinucléoline en tant que radiosensibiliseurs et agents de contraste d'imagerie par résonance magnétique (irm) et/ou en rayons x

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468758B1 (en) * 1998-09-23 2002-10-22 Corixa Corporation Compositions and methods for ovarian cancer therapy and diagnosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468758B1 (en) * 1998-09-23 2002-10-22 Corixa Corporation Compositions and methods for ovarian cancer therapy and diagnosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PORKKA ET AL: "A Fragment of the HMGN2 Protein Homes to the Nuclei of Tumor Cells and Tumor Endothelial Cells In Vivo", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 11, May 2002 (2002-05-01), pages 7444 - 7449, XP002904203 *
WALKER R. ET AL.: "The Partial Amino Acid Sequence of a Non-Histone Chromosomal Protein", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 73, no. 1, November 1976 (1976-11-01), pages 72 - 78, XP024845966, DOI: doi:10.1016/0006-291X(76)90498-8 *

Also Published As

Publication number Publication date
WO2003087124A2 (fr) 2003-10-23
AU2003228431A8 (en) 2003-10-27
AU2003228431A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
WO2001008636A8 (fr) Polypeptides et polynucleotides ameliorant la reactivite immunitaire a la proteine her-2
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
ATE330967T1 (de) An her2 bindende peptidverbindungen
WO2003087124A3 (fr) Peptides hmgn2 et molecules associees a ecotaxie selective vers des vaisseaux sanguins tumoraux et cellules tumorales
WO2003059951A8 (fr) Anticorps anti-igf-ir et leurs applications
MXPA04004417A (es) Anticuerpo anti-tnf alfa modificado.
WO2005058967A8 (fr) Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
RU2009114161A (ru) Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника
EP1194164B8 (fr) Peptides proteiniques du prion et utilisations associees
EP2535355A3 (fr) Anticorps diriges contre CD38 pour le traitement du myelome multiple
AU2003296330A1 (en) Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
EP2343318A3 (fr) Anticorps se liant à un fragment C-terminal de l'apolipoprotein E
CA2560278A1 (fr) Proteines bouganine, cytotoxines et leurs procedes et utilisations
WO2006028429A3 (fr) Peptide pour cibler l'antigene prostatique membranaire specifique
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
WO2006087637A3 (fr) Anticorps
WO2005122379A3 (fr) Ligands d'integrine alpha-4 beta-1 destines a l'imagerie et utilises en therapie
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
CA2579523A1 (fr) Molecules de liaison destinees au traitement et a la detection du cancer
WO2007018619A3 (fr) Agents therapeutiques chimeriques
EP2431050A8 (fr) Procédés pour traiter le cancer au moyen d'IL-21 et une thérapie par anticorps monoclonaux
EP2017343A3 (fr) Domaines de liaison à base de protéine A avec activités souhaitables
WO2001085777A3 (fr) Peptides therapeutiques formant des pores
AU6921300A (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
WO2006083562A3 (fr) Procede et conjugues a composants multiples permettant de traiter le cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP